SCHEDULE 13G/A: Paradigm BioCapital Divests Entire Stake in Pliant Therapeutics, Amends SEC Filing to Zero Ownership
Ownership Disclosure Amendment
Paradigm BioCapital Advisors LP and its affiliated entities have filed an amendment to their Schedule 13G, indicating they no longer hold a reportable beneficial ownership stake in Pliant Therapeutics, Inc. as of March 31, 2025.
Summary
- Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
- The filing indicates that as of March 31, 2025, the Reporting Persons collectively hold 0.0% beneficial ownership of Pliant Therapeutics, Inc.'s Common Stock.
- This amendment follows a previous Schedule 13G filing on October 10, 2024, which reported beneficial ownership by the Fund and separately managed accounts.
- Each Reporting Person disclaims beneficial ownership of any Common Stock other than what was directly beneficially owned by them.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the complete divestment of a stake by an institutional investor, which can be interpreted as a lack of continued conviction, although the filing itself is purely factual.
Negatives
- The divestment of an entire stake by an institutional investor like Paradigm BioCapital could be perceived as a negative signal regarding their long-term outlook or conviction in Pliant Therapeutics, Inc.
Future Outlook
The document does not contain any forward-looking statements or guidance from Pliant Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance.
Industry Context
This filing is a routine disclosure of institutional ownership changes, common in the biotechnology and pharmaceutical sectors. It reflects a portfolio adjustment by an investment firm rather than a direct operational or strategic update from Pliant Therapeutics, Inc. itself.
Stakeholder Impact
- Shareholders may view the complete divestment by an institutional investor as a negative signal, potentially influencing investor sentiment and the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 2024-10-10 | Date of the original Schedule 13G filing by the Reporting Persons. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G Amendment, reflecting 0.0% beneficial ownership. |
| 2025-05-15 | Signature date of the Schedule 13G Amendment. |
Keywords
Pliant Therapeutics, SEC filing, Schedule 13G, beneficial ownership, institutional investor, Paradigm BioCapital, divestment, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.